Viatris price target raised to $20 from $18 at Truist

Truist raised the firm’s price target on Viatris (VTRS) to $20 from $18 and keeps a Buy rating on the shares. The company’s Q1 results featuring a 5% revenue beat and 10% operational EBITDA growth represent a clear pivot point for investors who have sidelined the name while awaiting proof of consistent execution, the analyst tells investors in a research note.